Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$23,200.00

Protein-Protein Interactions between TDP-43 and p65 from NF-kB using NMR and modelling

EF 2013-14

Résumé
Amyotrophic Lateral Sclerosis (ALS) is a rare but devastating neurodegenerative disease. Key symptomsinclude muscle wasting and weakness involving musculature. Diagnosis is followed in >95% of the cases bydeath, usually from respiratory failure. Onset of ALS typically occurs in people aged between 50 and 65 yearsof age, but recently more and more cases are being reported at a younger age. This latter fact and the ageing ofCanada's population signify that there is a great need to find novel medicines to slow down or stop theprogression of ALS.Recent research has identified TAR DNA-binding protein 43 (TDP-43) as a causative agent of ALS. TDP-43consists of 4 distinct domains, one of which is a RNA-binding domains (RRM-1). Many studies suggest thatALS is a consequence of TDP-43 aggregating in motor neurons. More recent work, however, suggests thatTDP-43 dysregulation may be the result of protein-protein interactions between TDP-43 and the p65 subunit oftranscription factor nuclear factor kappa B (NF-kB, an inflammation-regulating protein). ImStar Therapeutics isdeveloping novel medicines directed at TDP-43 Associated NF-kB Activation. This activation leads toexaggerated immune responses resulting in neuro-inflammation and motor neuron destruction. Inhibition ofthis pathway in a mouse model of ALS produced substantial improvements in disease and motor functionindicating that this is an important new target for drug development.RRM-1 has been implicated in both the aggregation and dysregulation scenarios. Surprisingly, however, thereare few studies at the molecular level which clearly demonstrate how RRM-1 binds to other proteins or itself. Itis therefore the aim of this project to identify binding interactions between RRM-1 and p65, as well aspotentially between RRM-1 and itself. Such information is key to ImStar's goals of therapeutics development.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
452661-2013
Name nom
Straus, Suzana
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
23200
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3404
Research subject group en
Physical chemistry
Research subject group fr
Chimie physique
Research subject en
Biophysical chemistry
Research subject fr
Chimie biophysique
Partie
1
Nb partie
1
Application title
Protein-Protein Interactions between TDP-43 and p65 from NF-kB using NMR and modelling
Keyword
NSERC
Application summary
Amyotrophic Lateral Sclerosis (ALS) is a rare but devastating neurodegenerative disease. Key symptomsinclude muscle wasting and weakness involving musculature. Diagnosis is followed in >95% of the cases bydeath, usually from respiratory failure. Onset of ALS typically occurs in people aged between 50 and 65 yearsof age, but recently more and more cases are being reported at a younger age. This latter fact and the ageing ofCanada's population signify that there is a great need to find novel medicines to slow down or stop theprogression of ALS.Recent research has identified TAR DNA-binding protein 43 (TDP-43) as a causative agent of ALS. TDP-43consists of 4 distinct domains, one of which is a RNA-binding domains (RRM-1). Many studies suggest thatALS is a consequence of TDP-43 aggregating in motor neurons. More recent work, however, suggests thatTDP-43 dysregulation may be the result of protein-protein interactions between TDP-43 and the p65 subunit oftranscription factor nuclear factor kappa B (NF-kB, an inflammation-regulating protein). ImStar Therapeutics isdeveloping novel medicines directed at TDP-43 Associated NF-kB Activation. This activation leads toexaggerated immune responses resulting in neuro-inflammation and motor neuron destruction. Inhibition ofthis pathway in a mouse model of ALS produced substantial improvements in disease and motor functionindicating that this is an important new target for drug development.RRM-1 has been implicated in both the aggregation and dysregulation scenarios. Surprisingly, however, thereare few studies at the molecular level which clearly demonstrate how RRM-1 binds to other proteins or itself. Itis therefore the aim of this project to identify binding interactions between RRM-1 and p65, as well aspotentially between RRM-1 and itself. Such information is key to ImStar's goals of therapeutics development.